Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00517361
Recruitment Status : Terminated (This study has been terminated due to poor accrual)
First Posted : August 16, 2007
Results First Posted : April 15, 2014
Last Update Posted : April 15, 2014
Genentech, Inc.
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: carboplatin Drug: bevacizumab Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer
Study Start Date : August 2007
Actual Primary Completion Date : April 2011
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Carboplatin + Avastin Drug: carboplatin
AUC 6 in 250mL saline IV over 30 minutes
Drug: bevacizumab
15mg/kg in 100mL saline IV over 60 - 90 minutes
Other Name: Avastin

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Up to 5 years ]
    Progression is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000], as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: Up to 5 years ]
    Response is defined using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]: Complete Response (CR), Disappearance of all target lesions or disappearance of all non-target lesions and normalization of tumor marker level; Partial Response (PR), At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started, or persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

  2. Duration of Response [ Time Frame: Up to 5 years ]
  3. Correlation of Response to BRCA1 Methylation Status [ Time Frame: Up to 5 years ]
    The methylation status of the tumor is defined using Methylation Specific polymerase chain reaction and/or pyrosequencing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have pathologically confirmed ER, PR and HER2/neu negative (FISH ratio of <2.0 or IHC <1+) metastatic breast cancer. Locally advanced or recurrent disease is also eligible.
  • Patients must have measurable disease
  • Patients must not have received prior chemotherapy for metastatic breast cancer (not including adjuvant therapy). Patients should be > 4 weeks from their most recent chemotherapy or radiation therapy treatment.
  • Age >18 years
  • ECOG performance status <1 (Karnofsky >80%).
  • Patients must have normal organ and marrow function as defined below:
  • absolute neutrophil count >1,500/uL
  • platelets >100,000/uL
  • total bilirubin within normal institutional limits
  • AST(SGOT)/ALT(SGPT) <2.5X institutional upper limit of normal
  • creatinine within normal institutional limits OR creatinine clearance>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • PT INR < 1.5 (Unless patient is on anticoagulation)
  • urine protein <1+
  • Tissue from the primary tumor must be available for correlative studies
  • Women of child-bearing potential must agree to use adequate contraception
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients who have had prior therapy with platinum agents or a VEGF inhibitor are not eligible.
  • Patients may not be receiving any other investigational agents.
  • Patients with known brain metastases will be excluded
  • Patients may have had prior radiation therapy, provided the patient has measurable disease and there has been clear progression since the completion of radiation therapy. Patients who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to therapy administered more than 4 weeks earlier will be excluded.
  • Patients with significant cardiac dysfunction will be excluded
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study, breastfeeding should be discontinued.
  • HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with carboplatin or the other agents administered during the study.
  • Patients with evidence of bleeding diathesis or coagulopathy.
  • Patients with inadequately controlled hypertension will be excluded
  • Patients who have had a stroke or TIA within 6 months of registration will be excluded.
  • Patients with a history of hypertensive crisis or hypertensive encephalopathy will be excluded.
  • Patients with a history of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months of registration.
  • Patient with history of serious non-healing wound, ulcer or bone fracture.
  • Patients with major surgery, open biopsy, or significant traumatic injury within 28 days of registration or anticipated need for surgery during course of study treatment.
  • Patients with a history core biopsy or other minor surgery, excluding venous access device (VAD) placement, within 7 days of registration.
  • Patients with active second malignancy.
  • Known hypersensitivity to any component of bevacizumab (Avastin®).
  • Peripheral neuropathy > Grade 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00517361

United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Oncology Specialists
Park Ridge, Illinois, United States, 60068
Sponsors and Collaborators
University of Chicago
Genentech, Inc.
Principal Investigator: Rita Nanda, MD University of Chicago

Responsible Party: University of Chicago Identifier: NCT00517361     History of Changes
Other Study ID Numbers: 15578A
First Posted: August 16, 2007    Key Record Dates
Results First Posted: April 15, 2014
Last Update Posted: April 15, 2014
Last Verified: March 2014

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents